(FDA News Release, December 1, 2017)

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.

Read more here:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587378.htm

 

Access other Therapeutic Areas:


 

New & Noteworthy